Article
Medicine, General & Internal
Nicolas Bertrand, Pierre Guerreschi, Nicole Basset-Seguin, Philippe Saiag, Alain Dupuy, Sophie Dalac-Rat, Veronique Dziwniel, Cesar Depoortere, Alain Duhamel, Laurent Mortier
Summary: Neoadjuvant vismodegib treatment reduces the risk of surgery for patients with locally advanced basal cell carcinoma, minimizing the functional and aesthetic consequences of surgery.
Article
Dermatology
Helene Marescassier, Lea Dousset, Marie Beylot-Barry, Philippe Celerier, Loic Vaillant, Christophe Bedane, Franck Leclere, Ewa Wierzbicka-Hainaut, Marie Masson Regnault
Summary: In a retrospective multicenter study, factors associated with non-response to vismodegib in patients with locally advanced basal cell carcinomas (laBCC) were identified. Muscle involvement, history of radiotherapy, and intermittent use of vismodegib were significantly associated with non-response. Further studies are needed to confirm these findings due to the limited sample size.
Article
Ophthalmology
Assaf Gershoni, Alon Tiosano, Meydan Ben Ishai, Edward Barayev, Guy J. Ben Simon, Iftach Yassur
Summary: The study evaluated the impact of locally advanced periocular basal cell carcinoma (POLA-BCC) on health-related quality of life (HRQoL) and the efficacy of vismodegib treatment. Results showed that patients with POLA-BCC had significantly impaired overall functioning at baseline, but demonstrated significant improvement at the last follow-up.
Article
Dermatology
Mustafa Gurbuz, Izzet Dogan, Erman Akkus, Hande Ermis, Gungor Utkan, Sezai Vatansever, Faruk Tas
Summary: The study evaluated the efficacy of vismodegib treatment in locally advanced and metastatic basal cell carcinoma, showing it was well tolerated and effective in real-world settings. Treatment responses were most commonly seen within 2 months of initiation, with chemotherapy post-vismodegib showing significant improvement in overall survival compared to no treatment or surgery. The most common adverse events included fatigue, muscle spasms, alopecia, and weight loss.
DERMATOLOGIC THERAPY
(2021)
Article
Dermatology
Tanja Mesti, Masa Sever, Janja Ocvirk
Summary: Vismodegib has demonstrated significant efficacy in the treatment of laBCC, multiple BCC, and G-G Syn patients in Slovenia, achieving disease control rates of 95% to 100%.
Article
Oncology
Diya M. Sabu, Jeska Kroes, Charles Gilham, Ann Fleming, Fergal C. Kelleher
Summary: Basal cell carcinomas are common in Caucasian populations, with the Hedgehog pathway playing a significant role in their development. This case highlights the dramatic response of an elderly patient with untreated sporadic Basal cell carcinoma to the Hedgehog pathway inhibitor Vismodegib, enabling definitive treatment to be pursued.
CURRENT PROBLEMS IN CANCER
(2021)
Article
Dermatology
Veronica Ruiz-Salas, Sebastian Podlipnik, Alejandra Sandoval-Clavijo, Onofre Sanmartin-Jimenez, Eduardo Bernia-Petit, Montserrat Bonfill-Orti, Patricia Bassas-Freixas, Mireia Yebenes-Marsal, Angeles Florez-Menendez, Joaquim Sola-Ortigosa, Miquel Just-Sarobe, Rafael S. Aguayo-Ortiz, Emili Masferrer i Niubo, Monica Quintana-Codina, Gustavo Deza, Ane Jaka, Maria Jose Fuentes, Javier Canueto, Agusti Toll
Summary: This study analyzed the therapeutic management and evolution of relapses and lack of response in patients with locally advanced and/or multiple basal cell carcinomas who received vismodegib in a real-life multicentre setting. The results showed that vismodegib is effective in routine clinical practice, with a low risk of recurrence after achieving complete response and feasible rechallenge with vismodegib, which resulted in a good response in most patients.
Article
Oncology
Laura Eibenschutz, Silvia Caputo, Emanuela Camera, Anna Carbone, Vitaliano Silipo, Emilia Migliano, Caterina Aurizi, Carlo Cota, Pasquale Frascione, Barbara Bellei
Summary: Nevoid basal cell carcinoma syndrome (NBCCS) is a genetic disorder that predisposes individuals to basal cell carcinoma (BCC) due to mutations in genes related to the Hedgehog (Hh) pathway. Somatic mutations in this pathway are associated with sporadic BCC, and targeting this pathway with drugs like vismodegib and sonidegib could potentially be a therapeutic option. These drugs impact fibroblast functions supporting tumor growth and could be considered for BCC therapy regardless of the mutation status of Hh components in neoplastic cells.
Article
Dermatology
Ralf Gutzmer, Carmen Loquai, Caroline Robert, Brigitte Dreno, Alexander Guminski, Karl Lewis, Ramon Arntz, Serena Martelli, Nicholas Squittieri, Meenal Kheterpal
Summary: This analysis compared the incidence and onset of adverse events in patients treated with sonidegib and vismodegib for basal cell carcinoma. Sonidegib-treated patients experienced lower incidence and delayed onset of adverse events compared to those treated with vismodegib.
DERMATOLOGY AND THERAPY
(2021)
Article
Dermatology
Shane D. B. Smith, Callisia N. Clarke, Melanie A. Clark, Amy K. Harker-Murray, Olayemi Sokumbi
Summary: Basal cell carcinoma is the most commonly diagnosed cutaneous cancer in the United States, with about 90% of patients having a mutation in the hedgehog-signaling pathway. Most patients have an excellent prognosis with surgical treatment, but some may experience cosmetic or functional impairment. Vismodegib, a hedgehog pathway inhibitor, has shown success in treating locally advanced BCC patients.
AMERICAN JOURNAL OF DERMATOPATHOLOGY
(2021)
Article
Dermatology
Martin Kaatz, Peter Mohr, Elisabeth Livingstone, Michael Weichenthal, Alexander Kreuter, Claudia Pfoehler, Ulrike Leiter, Jens Ulrich, Jochen Sven Utikal, Ralf Gutzmer, Rudolf Herbst, Dirk Schadendorf
Summary: The non-interventional study JONAS conducted in Germany aimed to enhance understanding of the effectiveness, safety, and utilization of the oral selective hedgehog pathway inhibitor vismodegib in clinical practice. The results confirmed previous findings, demonstrating favorable responses and manageable safety of vismodegib in patients with locally advanced basal cell carcinomas.
ACTA DERMATO-VENEREOLOGICA
(2022)
Article
Oncology
Riccardo Pampena, Gabriele Parisi, Mattia Benati, Stefania Borsari, Michela Lai, Giovanni Paolino, Anna Maria Cesinaro, Silvana Ciardo, Francesca Farnetani, Sara Bassoli, Giuseppe Argenziano, Giovanni Pellacani, Caterina Longo
Summary: Infiltrative basal cell carcinoma (BCC) has a higher risk for post-surgical recurrence compared to low-aggressive superficial and nodular BCC. This study aimed to define clinical and dermoscopic criteria to differentiate infiltrative BCC from the common types. The research identified distinct clinical and dermoscopic features of infiltrative BCC, improving pre-surgical recognition and reducing recurrence risk.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Alon Kahana, Shelby P. Unsworth, Christopher A. Andrews, May P. Chan, Scott C. Bresler, Christopher K. Bichakjian, Alison B. Durham, Hakan Demirci, Victor M. Elner, Christine C. Nelson, Denise S. Kim, Shannon S. Joseph, Paul L. Swiecicki, Frances P. Worden
Summary: The study tested the hypothesis that the use of the hedgehog inhibitor vismodegib could improve vision-related outcomes in patients with orbital and extensive periocular BCC, successfully preserving globe and visual function. Results showed that most patients maintained stable or improved visual assessment scores after treatment with vismodegib, with a majority experiencing complete tumor regression.
Article
Dermatology
Justin Tong, Brandon Mitchell, Kathryn Roth, Diane Logan, Scott Ernst
Summary: This study aimed to explore the efficacy of vismodegib in treating advanced basal cell carcinoma, with half of the patients achieving complete response and a significant number becoming eligible for surgery or radiotherapy. However, treatment-related adverse effects remained a important limiting factor in treatment duration.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
(2022)
Article
Dermatology
J. Weis, C. Grote, M. Weichenthal, A. Hauschild
Summary: This case study discusses the treatment experience of a 78-year-old female patient with skin cancer. The patient underwent systemic treatment with cemiplimab and sonidegib, achieving significant therapeutic efficacy.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Geriatrics & Gerontology
Geoffrey Alan Potts, Maria Yadira Hurley
CLINICS IN GERIATRIC MEDICINE
(2013)
Letter
Dermatology
Brett C. Neill, Nicholas Golda, Edward W. Seger, Jo Wick, Jacob Whitsitt, Alison Huber, Thomas Chu, Geoffrey A. Potts, Peter Chow, Sarah Moore, Joseph W. Fakhoury, Anand Rajpara, Thomas L. H. Hocker
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2020)
Editorial Material
Surgery
Luke Horton, Fatima Fahs, Amrish Jain, Geoffrey Potts
AMERICAN JOURNAL OF TRANSPLANTATION
(2020)
Review
Dermatology
Madeline J. Adelman, Lisa M. Bedford, Geoff A. Potts
Summary: The hair supplement industry is vast and rapidly growing, with patients often turning to oral supplements for hair concerns. While some oral supplements have strong evidence supporting their use, many ingredients have not been tested in clinical trials or have only been tested in animals.
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2021)
Review
Dermatology
Geoffrey A. Potts, Taylor Adlam, Sarah C. Stierman, Meena Moossavi, Darius Mehregan
Summary: Pleomorphic fibromas are rare flesh-colored benign neoplasms with histopathologic findings of nuclear pleomorphism. Immunohistochemical staining and light microscopy examination can help characterize these lesions.
AMERICAN JOURNAL OF DERMATOPATHOLOGY
(2021)
Article
Dermatology
Sandra Oska, Lisa M. Bedford, Geoffrey A. Potts
Summary: A 13-month-old boy developed alopecia totalis two months after an episode of hand-foot-and-mouth disease, suggesting a potential link between viral infection and autoimmune response leading to hair loss. Further research is needed to investigate the pathophysiology of alopecia totalis triggered by viral infection.
PEDIATRIC DERMATOLOGY
(2021)
Article
Dermatology
Mehdi Farshchian, Geoffrey A. Potts
Summary: A one-month-old female patient developed severe hypertriglyceridaemia as a side effect of treating an ulcerating infantile hemangioma with systemic propranolol. Triglyceride levels returned to normal rapidly after discontinuation of the medication, and follow-up revealed normalization of the lipid profile. Further research is needed to explore the association of systemic propranolol with hypertriglyceridaemia.
AUSTRALASIAN JOURNAL OF DERMATOLOGY
(2021)
Review
Dermatology
Jenna Yousif, Mehdi Farshchian, Geoffrey A. Potts
Summary: With the growing cosmeceutical market for nail products, there is an increasing need for dermatologists to provide evidence-based information to patients regarding over-the-counter products and supplements for nail growth. However, these products are not required to undergo efficacy and safety assessment by the Food and Drug Administration, leading to financial and health consequences for patients. This review discusses available oral nail growth products, their mechanisms of action, and potential side effects.
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2022)
Letter
Dermatology
Muhammad Osto, Salam A. Smidi, Amira Alnabolsi, Rafey Rehman, Geoffrey Potts
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Dermatology
Mehdi Farshchian, Geoffrey Potts, Arash Kimyai-Asadi, Darius Mehregan, Steven Daveluy
JOURNAL OF DRUGS IN DERMATOLOGY
(2020)
Meeting Abstract
Health Care Sciences & Services
Bassam Yaghmour, Geoffrey Potts, George Yagmour, Sean Drake
JOURNAL OF GENERAL INTERNAL MEDICINE
(2011)
Article
Dermatology
Vivian Liu, Mehdi Farshchian, Geoffrey A. Potts
Summary: Hyperhidrosis is a common condition that impacts quality of life, with various treatment options available including topical therapy, surgery, and medications. Choosing the appropriate treatment can effectively control symptoms and improve the patient's quality of life.
JOURNAL OF DRUGS IN DERMATOLOGY
(2021)